Selected article for: "CRS cytokine release syndrome and cytokine release syndrome"

Author: Sheianov, Mikhail V; Udalov, Yurii D; Ochkin, Sergei S; Bashkov, Andrei N; Samoilov, Aleksandr S
Title: Pulse Therapy With Corticosteroids and Intravenous Immunoglobulin in the Management of Severe Tocilizumab-Resistant COVID-19: A Report of Three Clinical Cases
  • Cord-id: 7g1y6aoa
  • Document date: 2020_7_7
  • ID: 7g1y6aoa
    Snippet: We present the cases of three patients with severe, life-threatening coronavirus disease 2019 (COVID-19) who had failed to achieve substantial improvement on intial treatment. They subsequently received pulse therapy with methylprednisolone [1,000 mg/day intravenously (IV) for three consecutive days] and IV immunoglobulin (20 g/day). This treatment regimen was associated with a prompt resolution of respiratory failure, elimination of clinical manifestations of the cytokine release syndrome (CRS)
    Document: We present the cases of three patients with severe, life-threatening coronavirus disease 2019 (COVID-19) who had failed to achieve substantial improvement on intial treatment. They subsequently received pulse therapy with methylprednisolone [1,000 mg/day intravenously (IV) for three consecutive days] and IV immunoglobulin (20 g/day). This treatment regimen was associated with a prompt resolution of respiratory failure, elimination of clinical manifestations of the cytokine release syndrome (CRS), and reversal of pulmonary CT changes. The treatment was generally safe and well-tolerated. There was no evidence of protracted persistence of the virus in the patients. Further randomized controlled trials are required to better understand the efficacy and safety of high-dose methylprednisolone and IV immunoglobulin, separately or in combination with each other, in the treatment of severe, life-threatening COVID-19.

    Search related documents:
    Co phrase search for related documents
    • aberrant excessive and acute respiratory distress syndrome: 1, 2, 3, 4, 5
    • aberrant excessive and acute respiratory failure: 1
    • activity relationship and acute respiratory failure: 1
    • activity relationship and lung change: 1
    • acute ards respiratory distress syndrome and admission chest: 1, 2, 3, 4, 5, 6, 7
    • acute ards respiratory distress syndrome and admission chest ct: 1, 2, 3
    • acute ards respiratory distress syndrome and admission lung: 1, 2, 3, 4, 5, 6, 7, 8, 9
    • acute ards respiratory distress syndrome and low flow oxygen: 1
    • acute ards respiratory distress syndrome and low tidal volume ventilation: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22
    • acute ards respiratory distress syndrome and lung change: 1, 2, 3
    • acute ards respiratory distress syndrome and lung impairment: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12
    • acute respiratory distress syndrome and admission chest: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16
    • acute respiratory distress syndrome and admission chest ct: 1, 2, 3, 4, 5, 6
    • acute respiratory distress syndrome and admission chest ct imaging: 1
    • acute respiratory distress syndrome and admission lung: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15
    • acute respiratory distress syndrome and low flow oxygen: 1, 2, 3
    • acute respiratory distress syndrome and low tidal volume ventilation: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
    • acute respiratory distress syndrome and lung change: 1, 2, 3, 4, 5, 6
    • acute respiratory distress syndrome and lung impairment: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14